Non-oxime inhibitors of B-Raf(V600E) kinase.

The development of inhibitors of B-Raf(V600E) serine-threonine kinase is described. Various head-groups were examined to optimize inhibitor activity and ADME properties. Several of the head-groups explored, including naphthol, phenol and hydroxyamidine, possessed good activity but had poor pharmacokinetic exposure in mice. Exposure was improved by incorporating more metabolically stable groups such as indazole and tricyclic pyrazole, while indazole could also be optimized for good cellular activity.

[1]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[2]  Mike Welch,et al.  Potent and selective pyrazole-based inhibitors of B-Raf kinase. , 2008, Bioorganic & medicinal chemistry letters.

[3]  David M. Wilson,et al.  The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. , 2006, Bioorganic & medicinal chemistry letters.

[4]  S. Nilsson,et al.  Estrogen receptor beta-subtype selective tetrahydrofluorenones: use of a fused pyrazole as a phenol bioisostere. , 2006, Bioorganic & medicinal chemistry letters.

[5]  B. Clement,et al.  Oxygen-insensitive enzymatic reduction of oximes to imines. , 2006, Biochemical pharmacology.

[6]  C. Peyssonnaux,et al.  The Raf/MEK/ERK pathway: new concepts of activation , 2001, Biology of the cell.

[7]  J. Becker,et al.  Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis , 2004, Journal of carcinogenesis.

[8]  A. Galetin,et al.  Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[9]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[10]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[11]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[12]  M. A. García-Cabezas,et al.  The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. , 2006, Endocrine-related cancer.

[13]  K. Czene,et al.  BRAF mutations in metastatic melanoma: a possible association with clinical outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  B. Clement.  REDUCTION OF N-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES , 2002, Drug metabolism reviews.

[15]  D. Polsky,et al.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.

[16]  Erica A Golemis,et al.  Selective Raf inhibition in cancer therapy , 2007, Expert opinion on therapeutic targets.